Disrupted Access to Prescription Stimulant Medications Could Increase Risk of Injury and Overdose

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Center for Preparedness and Response.
• Description:
  Distributed via the CDC Health Alert Network
  
  June 13, 2024, 1:00 PM ET
  
  CDCHAN-00510
  
  The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to inform public health officials, clinicians, and affected patients, their families, and caregivers about potential disrupted access to care among individuals taking prescription stimulant medications and possible increased risks for injury and overdose. On June 13, 2024, the U.S. Department of Justice announced a federal health care fraud indictment against a large subscription-based telehealth company that provides attention-deficit/hyperactivity disorder (ADHD) treatment to patients ages 18 years and older across the United States. Patients who rely on prescription stimulant medications to treat their ADHD and have been using this or other similar subscription-based telehealth platforms could experience a disruption to their treatment and disrupted access to care. A disruption involving this large telehealth company could impact as many as 30,000 to 50,000 patients ages 18 years and older across all 50 U.S. states.
  
  
• Subjects:
  Attention Deficit Disorder With Hyperactivity/drug Therapy Health Services Accessibility Telemedicine
• Source:
  HAN ; 510
• Series:
  Health Alert Network
• Document Type:
  HAN Health Advisory
• Place as Subject:
  United States
• Issue:
  510
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:bc7caf3cbe51507ac657db0d8b59d6f8db23ac437738c3e02c410e03902d82dac5ef78d544579de71b758341de7435d57014c7838142d7964c71e31cd2169269
• Download URL:
  https://stacks.cdc.gov/view/cdc/157466/cdc_157466_DS1.pdf
• File Type:
  [PDF - 108.87 KB ]